-
Product Insights
Prader-Willi Syndrome (PWS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Prader-Willi Syndrome (PWS) - Drugs In Development, 2023’, provides an overview of the Prader-Willi Syndrome (PWS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Pediatric Diffuse Intrinsic Pontine Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Pediatric Diffuse Intrinsic Pontine Glioma - Drugs In Development, 2023’, provides an overview of the Pediatric Diffuse Intrinsic Pontine Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pediatric Diffuse Intrinsic Pontine Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Medulloblastoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Medulloblastoma - Drugs In Development, 2023’, provides an overview of the Medulloblastoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Medulloblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Pontine Glioma – Drugs In Development, 2023
Global Markets Direct’s, ‘Pontine Glioma - Drugs In Development, 2023’, provides an overview of the Pontine Glioma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pontine Glioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Non Alcoholic Fatty Liver Disease (NAFLD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Non Alcoholic Fatty Liver Disease (NAFLD) - Drugs In Development, 2023’, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Brain Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Brain Cancer - Drugs In Development, 2023’, provides an overview of the Brain Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Brain Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Glioblastoma Multiforme (GBM) - Drugs In Development, 2023’, provides an overview of the Recurrent Glioblastoma Multiforme (GBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Thematic Analysis
Low Cost Evolution Travel and Tourism – Thematic Intelligence
Low-Cost Evolution Travel and Tourism Thematic Report Overview Travel companies are targeting a wider range of customers as airfares and hotel tariffs have become affordable in recent years. The travel industry now encompasses every type of traveler, and this has resulted in the rising popularity of low-cost travel and tourism operators. Travel apps such as Airbnb and Uber have been at the forefront of the low-cost evolution. These apps shape travelers’ spending habits by sending push notifications regarding last-minute deals...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibutamoren Mesylate in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibutamoren Mesylate in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibutamoren Mesylate in Metabolic Dysfunction-Associated Steatotic Liver...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibutamoren Mesylate in Growth Hormone Deficiency
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibutamoren Mesylate in Growth Hormone Deficiency report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibutamoren Mesylate in Growth Hormone Deficiency Drug Details: Ibutamoren...